SurvivorNet on MSN
A simpler delivery system: FDA approves subcutaneous injection version of powerful targeted drug isatuximab for multiple myeloma
A new under‑the‑skin version of isatuximab is now approved, giving multiple myeloma patients a much faster and more ...
Morning Overview on MSN
Multiple myeloma patients can now get the drug Sarclisa as a quick under-the-skin shot
People living with relapsed or refractory multiple myeloma now have a faster way to receive one of their key treatments. The ...
FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
In a merger between two subcutaneous drug delivery companies, Halozyme Therapeutics is paying $750 million in cash to acquire Elektrofi. Aside from the $750 million upfront payment, the deal also ...
The FDA has approved a subcutaneous version of isatuximab (Sarclisa Escena, Sanofi-Aventis) for several multiple myeloma (MM) ...
The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and only subcutaneously administered therapy for patients with epidermal growth ...
The FDA has approved a subcutaneous dose for initiation of lecanemab treatment in adults with Alzheimer’s disease, according ...
The U.S. Food and Drug Administration (FDA) today approved a weekly subcutaneous starting dose for Leqembi, marking the first ...
Y our oncologist may prescribe immunotherapy at various points in the cancer treatment journey. Immunotherapy is known to be especially effective in treating late-stage cancer that hasn’t responded to ...
Increasing number of product approvals by regulatory authorities for the treatment of cancer is expected to drive growth of the subcutaneous drug delivery market. For instance, in February 2019, ...
The Trump administration is closing a loophole that drugmakers could use to avoid negotiations when they add active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results